RGNX insider transaction filings
REGENXBIO Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-03. Screen RGNX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 8 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing by 1 insider — 102,603 shares, $949,381 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 2 filings by 1 insider — 58,494 shares, $718,232 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: purchase of 53,407 shares @ $9.36 ($499,676) by Ciongoli Gregory Austin, filed 2026-08-27.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Ciongoli Gregory Austin — Director | 1 | 2 legs · 102,603 sh · $949,381 | — | 2 |
| PAKOLA STEVE — Chief Medical Officer | 3 | — | 3 legs · 58,494 sh · $718,232 | 5 |
| Simpson Curran — Chief Executive Officer, Director | 1 | — | — | 3 |
| Chan Mitchell — Chief Financial Officer | 1 | — | — | 1 |
| Christmas Patrick J. — Chief Strategy & Legal Officer | 1 | — | — | 1 |
| Malzahn Craig — Chief Technology Officer | 1 | — | — | 1 |
Recent Form 4 filings — REGENXBIO Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Chan Mitchell — Chief Financial Officer | Tax withholding (F): 4,902 @ $9.32 | EDGAR |
| 2026-09-03 | 4 | Malzahn Craig — Chief Technology Officer | Tax withholding (F): 234 @ $9.32 | EDGAR |
| 2026-08-27 | 4 | Ciongoli Gregory Austin — Director | Grant/award (A): 15,432 @ $0 · Purchase (P): 49,196 @ $9.14 · Purchase (P): 53,407 @ $9.36 · Grant/award (A): 69,609 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | PAKOLA STEVE — Chief Medical Officer | Tax withholding (F): 7,468 @ $9.69 | EDGAR |
| 2026-08-04 | 4 | Christmas Patrick J. — Chief Strategy & Legal Officer | Tax withholding (F): 4,699 @ $9.69 | EDGAR |
| 2026-07-06 | 4 | PAKOLA STEVE — Chief Medical Officer | Option exercise (M): 2,161 @ $7.86 · Sale (S): 2,161 @ $13.64 · Option exercise (M): 2,161 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Simpson Curran — Chief Executive Officer, Director | Grant/award (A): 951 @ $7.00 · Grant/award (A): 1,453 @ $10.18 · Tax withholding (F): 6,818 @ $13.09 | EDGAR |
| 2026-07-01 | 4 | PAKOLA STEVE — Chief Medical Officer | Sale (S): 19,608 @ $11.04 · Option exercise (M): 36,725 @ $7.86 · Sale (S): 36,725 @ $12.86 · Option exercise (M): 36,725 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Bennett Jean — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Zachary Jennifer — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Glucksmann Alexandra — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Fox Allan M. — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Mills Kenneth T. — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Tasse Daniel — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | STUMP DAVID C — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | KARABELAS ARGERIS N — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | MIGAUSKY GEORGE V — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | PAKOLA STEVE — Chief Medical Officer | Sale (S): 15,309 @ $11.02 | EDGAR |
| 2026-03-12 | 4 | PAKOLA STEVE — Chief Medical Officer | Sale (S): 5,124 @ $10.35 | EDGAR |
| 2026-02-03 | 4 | PAKOLA STEVE — Chief Medical Officer | Tax withholding (F): 5,267 @ $11.16 | EDGAR |
| 2026-02-03 | 4 | Christmas Patrick J. — Chief Strategy & Legal Officer | Tax withholding (F): 4,700 @ $11.16 | EDGAR |
| 2026-01-29 | 4 | Mills Kenneth T. — Director | Option exercise (M): 225,000 @ $13.09 · Tax withholding (F): 221,753 @ $13.41 · Option exercise (M): 225,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Malzahn Craig — Chief Technology Officer | Grant/award (A): 65,847 @ $0 · Grant/award (A): 35,402 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Chan Mitchell — Chief Financial Officer | Grant/award (A): 73,749 @ $0 · Grant/award (A): 39,650 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | PAKOLA STEVE — Chief Medical Officer | Grant/award (A): 65,847 @ $0 · Grant/award (A): 35,402 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Christmas Patrick J. — Chief Strategy & Legal Officer | Grant/award (A): 73,749 @ $0 · Grant/award (A): 39,650 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Simpson Curran — Chief Executive Officer, Director | Grant/award (A): 144,864 @ $0 · Grant/award (A): 233,651 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Malzahn Craig — Chief Technology Officer | Tax withholding (F): 1,238 @ $14.40 | EDGAR |
| 2026-01-06 | 4 | PAKOLA STEVE — Chief Medical Officer | Tax withholding (F): 18,247 @ $14.40 | EDGAR |
| 2026-01-06 | 4 | Christmas Patrick J. — Chief Strategy & Legal Officer | Tax withholding (F): 9,793 @ $14.40 | EDGAR |
| 2026-01-06 | 4 | Simpson Curran — Chief Executive Officer, Director | Tax withholding (F): 18,559 @ $14.40 | EDGAR |
| 2025-10-10 | 4 | Simpson Curran — Chief Executive Officer, Director | Sale (S): 20,811 @ $12.62 | EDGAR |
| 2025-10-01 | 4 | Simpson Curran — Chief Executive Officer, Director | Sale (S): 7,624 @ $10.03 | EDGAR |
| 2025-09-12 | 4 | Simpson Curran — Chief Executive Officer, Director | Sale (S): 7,734 @ $10.02 | EDGAR |
| 2025-09-03 | 4 | Malzahn Craig — Chief Technology Officer | Tax withholding (F): 234 @ $8.93 | EDGAR |
| 2025-09-03 | 4 | Chan Mitchell — Chief Financial Officer | Tax withholding (F): 4,901 @ $8.93 | EDGAR |
| 2025-08-04 | 4 | Christmas Patrick J. — Chief Strategy & Legal Officer | Tax withholding (F): 4,699 @ $8.19 | EDGAR |
| 2025-07-03 | 4 | Simpson Curran — Chief Executive Officer, Director | Tax withholding (F): 4,701 @ $8.23 | EDGAR |
| 2025-06-03 | 4 | Fox Allan M. — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Zachary Jennifer — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Mills Kenneth T. — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Glucksmann Alexandra — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Bennett Jean — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Tasse Daniel — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | STUMP DAVID C — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | KARABELAS ARGERIS N — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | MIGAUSKY GEORGE V — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | Mills Kenneth T. — Director | Option exercise (M): 20,602 @ $3.76 · Sale (S): 20,602 @ $7.91 · Option exercise (M): 20,602 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Danos Olivier — Chief Scientific Officer | Tax withholding (F): 5,452 @ $8.07 | EDGAR |
| 2025-04-04 | 4 | Christmas Patrick J. — Chief Legal Officer | Tax withholding (F): 4,700 @ $8.07 | EDGAR |
Recent 8-K events — REGENXBIO Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-24 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RGNX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →